FDA PUBLIC MEETING STATEMENT, OPINION AND RECOMMENDATION Development and Regulation of Abuse-Deterrent Formulations of Opioid Medications; Public Meeting The meeting will focus on scientific and technical issues related

First Page		Document Content
Date: 2014-10-31 11:35:19 Alcohols Morphinans Ethers Euphoriants Opioid Morphine Food and Drug Administration Chemistry Organic chemistry Phenols		FDA PUBLIC MEETING STATEMENT, OPINION AND RECOMMENDATION Development and Regulation of Abuse-Deterrent Formulations of Opioid Medications; Public Meeting The meeting will focus on scientific and technical issues related Add to Reading List Source URL: www.ghlf.org Download Document from Source Website File Size: 91,36 KB Share Document on Facebook

	Microsoft Word - VLD Packet.FINAL DocID: 1rubZ - View Document
	Atlantic Pharmaceuticals Announces Successful Pre-IND Meeting with the FDA on Immediate Release, Abuse-Deterrent Hydrocodone Atlanta, GA., August 13, 2013. Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical compa DocID: 1rtjz - View Document
	TITAN PHARMACEUTICALS CORPORATE PRESENTATION SUNIL BHONSLE JUNE 2016 © 2016 TITAN PHARMACEUTICALS INC. NASDAQ:TTNP DocID: 1rsmr - View Document
	“Hokus-Pokus Palliative Care” Case Report Gabriela Popescu, MD, M.Sc. Palliative Care, FMH Internal Medicine Tumor Zentrum and Hirslanden Klinik Aarau DocID: 1rsfZ - View Document
	Sunil Bhonsle Mar 2015 Corporate Presentation DocID: 1rrwl - View Document